期刊文献+

Nrf2在不同肝癌细胞株中的表达及定位 被引量:2

Expression and distribution of Nrf2 in several hepatocellular carcinoma cell lines
下载PDF
导出
摘要 目的:观察红系衍生的核因子2相关因子2(Nrf2)在肝癌细胞株(HepG2、Hep3B、SMMC-7721)中的表达及分布情况。方法:应用流式细胞术测定Nrf2阳性细胞的比例,激光共聚焦观察Nrf2在3种细胞株中的定位情况,通过Westernblot测定Nrf2在不同细胞胞质及胞核中的表达差异。结果:流式细胞术测定Nrf2在HepG2、Hep3B和SMMC-77213种细胞中表达率分别为99.39%、99.94%和99.98%,激光共聚焦观察到Nrf2在3种肝癌细胞株胞质胞核中均有分布,但不同细胞的分布规律各不相同,Western blot结果显示:Nrf2在HepG2中以胞质分布为主,在Hep3B中胞质、胞核分布相当,在SMMC-7721中以胞核分布为主。结论:Nrf2在3种肝癌细胞株(HepG2、Hep3B、SMMC-7721)中均有表达,且在胞质胞核中均有分布,但在不同细胞中的分布规律各不相同,为下一步探讨肝癌细胞耐药机制的相关研究奠定了基础。 AIM: The aim of this study was to investigate the expression and the distribution of Nuclear factor-erythroid 2 p45-related factor 2(Nrf2) in several human hepatocellular cancer cell lines(HepG2,Hep3B,SMMC-7721).METHODS: Flow cytometry was used to figure out the percentages of Nrf2-positive cells in these three cell lines.The localization of Nrf2 was estimated by the laser confocal microsopy and the expression levels of Nrf2 in hepatocellular cancer cell lines were detected by Western blot analysis.RESULTS: The percentages of Nrf2 positive cells in HepG2,Hep3B,and SMMC-7721 were 99.39%,99.94%,and 99.98% through the flow cytometry.The laser confocal microsopy showed that Nrf2 mainly localized in the cytoplasm of HepG2 cells,distributed evenly in the cytoplasm and nucleus of Hep3B cells,and mainly localized in the nucleus of SMMC-7721 cells.Western blot analysis confirmed the result by the laser confocal microsopy.CONCLUSION: The data on the expression and localization of Nrf2 will be helpful for the following research on the role of Nrf2 in the drug resistance of hepatocellular carcinoma to chemotherapy.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2011年第6期608-610,共3页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30600744)
关键词 NRF2 肝癌细胞株 表达 定位 Nuclear factor-erythroid 2 p45-related factor 2 human hepatocellular cancer cell lines expression location
  • 相关文献

参考文献8

  • 1Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element[ J ]. Annu Rev Pharmacol Toxicol, 2003, 43:233 -260.
  • 2Cho JM, Manandhar S, Lee HR, et al. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance [ J ]. Cancer Lett, 2008, 260 ( 1 - 2 ) : 96 - 108.
  • 3Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer[ J]. Clin Cancer Res, 2009, 15(10): 3423-3432.
  • 4Loignon M, Miao W, Hu L, et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity tocarclnogens, to oxidative stress, and to chemotherapy[J]. Mol Cancer Ther, 2009, 8 (8): 2432 -2440.
  • 5Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keapl confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer[ J ]. Gastroenterology, 2008, 135 ( 4 ) : 1358 - 1368.
  • 6Wang X J, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 [ J ]. Carcinogenesis, 2008, 29(6) : 1235 - 1243.
  • 7Lau A, Villeneuve NF, Sun Z, et al. Dual roles of Nrf2 in cancer [J]. Pharmacol Res, 2008, 58(5 -6) : 262 -270.
  • 8Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1- NRF2 interaction in non-small-cell lung cancer [ J ]. PLoS Med, 2006, 3(10) : e420.

同被引文献13

  • 1Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer[ J]. Methods Mol Biol, 2010, 596( 1 ): 47 -76.
  • 2Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention[ J]. Toxicol Appl Pharmacol, 2010, 244( 1 ) : 66 -76.
  • 3Akhdar H, Loyer P, Rauch C, et al. Involvement of Nrf2 activation in resistance to 5-fluorouracil in human colon cancer I-IT-29 cells [ J ]. Eur J Cancer, 2009, 45 (12) : 2219-2227.
  • 4Homma S, Ishii Y, Morishima Y, et al. Nrf2 enhances cell proliferttion and resistance to anticancer drugs in human lung cancer[ J]. Clin Cancer Res, 2009, 15 (10) : 3423 -3432.
  • 5Kim JH, Bogner PN, Ramnath N, et al. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer[ J ]. Clin Cancer Res, 2007, 13 (13) : 3875-3882.
  • 6Zhang DD. The Nrf2-Keapl-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer [ J]. Antioxid Redox Signal, 2010, 13(11): 1623-1626.
  • 7Zhang DD. The Nrf2-Keapl-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer [ J ]. Antioxid Redox Signal, 2010, 13(11): 1623-1626.
  • 8Takahashi T, Sonobe M, Menju T, et al. Mutations in Keapl are a potential prognostic factor in resected non-small cell lung cancer[ J]. J Surg Oncol, 2010, 101 (6) : 500 -506.
  • 9Singh A, Misra V, Thimmulappa K, et al. Dysfunctional KEAP1NRF2 interaction in non-small-cell lung cancer [ J]. PLoS Med, 2006, 3(10) : e420.
  • 10Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keapl confers constitutive Nff2 activation and resistance to chemotherapy in gallbladder cancer[ J]. Gastroenterology, 2008, 135 (4) : 1358-1368.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部